Recently, the Lecheng Pilot for Drug Real World Data Application has seen a new breakthrough! The Inclisiran Injection of Novartis has been included in the pilot program again as the 12th product, for the “lipid-lowering monotherapy” indication this time. This product utilizes the retrospective real-world data collected in Lecheng to support the expanded indication of “lipid-lowering monotherapy”, making it the first product with expanded indication in the pilot program.